

Enhanced patient care through accelerated access to psychedelic therapy.

Albert Labs is the first psychedelic company leveraging Real World Evidence Studies to enhance patient care by accelerating access to psychedelic therapy in a hospital setting. Albert Labs will start with patients suffering from an urgent and unmet medical need of cancer related anxiety; and expand their therapy from the UK to the rest of the world.



- Albert Hofmann, 1938
Novartis Labs (Sandoz) , Basel
Switzerland.

Addressing mental health.

Current mental health treatments; SSRI's & SNRI's and other antidepressants are over 25 years old, relatively ineffective and can come with severe side effects.

+500 Million People

Suffer from anxiety and depression disorders worldwide.

Unmet medical need


Only **1 in 3** patients typically responding to treatment within 12 weeks.

Continued Success

Leading academics have already shown psychedelic medicines are a safe and effective.

Rethinking the clinical paradigm.

The average clinical trial takes **5-12 years** and costs over **half a billion dollars**. An increasing number of patients with mental health trauma can't wait this long for a new approach.



Watch our video

The Real World Evidence revolution.

Our aim is to use pragmatic **Real World Evidence** studies in collaboration with leading academic institutions in the UK & Europe. With the aim to generate clinically meaningful data and enhance physician experience in a broader range of patients validating and building on

existing clinical trials data. We believe it's the best way to ensure rapid, safe and appropriate access to reimbursed psychedelic medicines.

Clinical Studies



Real World Evidence



Vs

The immediate unmet need.

1.2 Million UK cancer patients suffer from psychiatric mood disorders. Cancer patients often develop a chronic, clinically significant syndrome of psychosocial distress having depressed mood, anxiety, and reduced quality of life as core features. **With up to 30 - 40% of cancer patients meeting criteria for a mood disorder.**

Cancer patients showed **major reductions in psychological stress, anxiety, and depression for up to seven months or longer after only a single dose administration of psilocybin.** For further studies showing the extraordinary clinical success see Appendix 1-3.